drugset
drugset / Trial / NCT00006485

Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors

NCT00006485 ↗

Phase 1 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Non-randomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining flavopiridol with irinotecan in treating patients who have locally advanced or metastatic solid tumors.

Timeline

Start
2000-09
Primary completion
2003-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject alvocidib Small molecule — Intravenous
Background Irinotecan Small molecule — Intravenous

Indications

cancer of unknown primary site